Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $65.32M |
| Net Income (Most Recent Fiscal Year) | $-81.89M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.68 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.53 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -108.62% |
| Net Margin (Trailing 12 Months) | -106.80% |
| Return on Equity (Trailing 12 Months) | -78.58% |
| Return on Assets (Trailing 12 Months) | -23.18% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.44 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.44 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.42 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.84 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.20 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 29.02M |
| Free Float | 25.69M |
| Market Capitalization | $447.19M |
| Average Volume (Last 20 Days) | 0.20M |
| Beta (Past 60 Months) | 0.96 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.48% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.99% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |